Celgene Co. (CELG) Holdings Lowered by Albion Financial Group UT

Albion Financial Group UT trimmed its stake in shares of Celgene Co. (NASDAQ:CELG) by 0.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 71,011 shares of the biopharmaceutical company’s stock after selling 662 shares during the quarter. Celgene comprises 1.6% of Albion Financial Group UT’s holdings, making the stock its 19th biggest position. Albion Financial Group UT’s holdings in Celgene were worth $10,355,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the business. BlackRock Inc. raised its holdings in shares of Celgene by 5.7% in the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after purchasing an additional 3,084,227 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Celgene by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after purchasing an additional 1,610,056 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Celgene by 11.5% in the 3rd quarter. Jennison Associates LLC now owns 14,962,407 shares of the biopharmaceutical company’s stock worth $2,181,818,000 after purchasing an additional 1,546,673 shares in the last quarter. FMR LLC raised its holdings in shares of Celgene by 5.9% in the 2nd quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock worth $1,635,643,000 after purchasing an additional 697,250 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in shares of Celgene by 3.3% in the 2nd quarter. Franklin Resources Inc. now owns 11,080,093 shares of the biopharmaceutical company’s stock worth $1,439,025,000 after purchasing an additional 349,974 shares in the last quarter. Institutional investors own 79.85% of the company’s stock.

A number of analysts recently commented on the stock. BidaskClub downgraded shares of Celgene from a “hold” rating to a “sell” rating in a report on Saturday. Piper Jaffray Companies reiterated a “hold” rating and issued a $104.00 target price on shares of Celgene in a report on Thursday. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $114.80 target price on the stock in a report on Wednesday. Cantor Fitzgerald set a $112.00 target price on shares of Celgene and gave the stock a “hold” rating in a report on Wednesday. Finally, Mizuho reiterated a “buy” rating and issued a $128.00 target price on shares of Celgene in a report on Wednesday. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $129.98.

Celgene Co. (NASDAQ:CELG) opened at $102.65 on Friday. Celgene Co. has a 1 year low of $94.55 and a 1 year high of $147.17. The company has a market cap of $81,560.00, a P/E ratio of 24.21, a P/E/G ratio of 0.65 and a beta of 1.77. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the previous year, the firm posted $1.58 earnings per share. The firm’s revenue was up 10.2% on a year-over-year basis. equities analysts anticipate that Celgene Co. will post 6.7 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Celgene Co. (CELG) Holdings Lowered by Albion Financial Group UT” was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3148392/celgene-co-celg-holdings-lowered-by-albion-financial-group-ut.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.